reports
Moody's Ratings affirms Eli Lilly's A1 rating; revises outlook to posi...
Moody's Ratings (Moody's) affirmed the ratings of Eli Lilly and Company ("Lilly") including the A1 senior unsecured notes and issuer rating. At the same tome Moody's also affirmed the (P)A1 senior unsecured shelf, (P)A1 senior unsecured medium term notes program and the Prime-1 short-term rating. Mo...
Eli Lilly & Co: 1 director
A director at Eli Lilly & Co sold 750 shares at 753.600USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Pelham Smithers
PSA Market Strategy: How Japan Transformed from a Bear Market to a Bul...
In our 2010 Japan Perspective, written close to the nadir of the bear market, we discussed what was wrong with Japan, but also what it was starting to do right. Fourteen years on, the Nikkei 225 - though not yet Topix - has hit a new all-time high. This report looks at how Japan built on those things that were going right, while also starting to address what else needed to be done, and looks at whether more is needed to be done if the market rally is to continue from here.
NVDA NVIDIA CORPORATION
LLY ELI LILLY AND COMPANY
FB FACEBOOK INC. CLASS A
9433 KDDI CORPORATION
6954 FANUC CORPORATION
8001 ITOCHU CORPORATION
6752 PANASONIC CORPORATION
6971 KYOCERA CORPORATION
8031 MITSUI & CO. LTD
4183 MITSUI CHEMICALS INC.
6723 RENESAS ELECTRONICS CORPORATION
6701 NEC CORP.
5401 NIPPON STEEL CORP.
4063 SHIN-ETSU CHEMICAL CO LTD
8035 TOKYO ELECTRON LTD.
6201 TOYOTA INDUSTRIES CORP.
7203 TOYOTA MOTOR CORP.
7270 SUBARU CORP
XOM EXXON MOBIL CORPORATION
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
TXG 10X GENOMICS INC CLASS A
BRK.A BERKSHIRE HATH-A
APPL APPLE INC - APPL - US
9810 NIPPON STEEL TRADING CORP
Moody's rates Eli Lilly's notes A1; stable outlook
Moody's Investors Service (Moody's) assigned an A1 rating to the new senior unsecured notes offering of Eli Lilly and Company ("Lilly"). There are no changes to Lilly's existing ratings including the A1 senior unsecured long-term rating and the Prime-1 short-term rating, or the stable outlook. RAT...
- Dominic Rose
- Naresh Chouhan
NOVO - Wegovy Peak Sales now $25bn (BUY, TP DKK 1500)
In this note, we increase our Wegovy peak by $10bn following SELECT, include 70% a chance of Medicare reimbursement, include the IRA impact in 2027 on Wegovy, show that SELECT makes Wegovy value for money, increase Wegovy stay time, we expect Wegovy to be added to AHA guidelines & thus anti-obesity drugs to be legitimised and finally, we increase our PT to DKK1500. The inclusion of Medicare adds $9bn to our peak sales and we cut our US price per scrip by 60% by 2028. Our highly conservative assu...
Moody's upgrades Eli Lilly to A1; stable outlook
Moody's Investors Service (Moody's) upgraded the senior unsecured long-term ratings of Eli Lilly and Company ("Lilly") to A1 from A2. At the same time, Moody's affirmed Lilly's Prime-1 commercial paper rating. In tandem with this action, Moody's revised the outlook to stable from positive. The upg...
- Brian Moretta
- Mark Thomas
- Martin Hall
- Riccardo Bindi
Hardman & Co Monthly: April 2023
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
WHR WHIRLPOOL CORPORATION
AMN AMN HEALTHCARE SERVICES INC.
WM WASTE MANAGEMENT INC.
TWI TITAN INTERNATIONAL INC.
PAYX PAYCHEX INC.
NDSN NORDSON CORPORATION
LLY ELI LILLY AND COMPANY
LIVN LIVANOVA PLC
KRNT KORNIT DIGITAL LTD.
KEYS KEYSIGHT TECHNOLOGIES INC
K KELLOGG COMPANY
JNJ JOHNSON & JOHNSON
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
HRL HORMEL FOODS CORPORATION
HAS HASBRO INC.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
FARO FARO TECHNOLOGIES INC.
EPAM EPAM SYSTEMS INC.
CORT CORCEPT THERAPEUTICS INCORPORATED.
CALX CALIX NETWORKS
BAX BAXTER INTERNATIONAL INC.
AOSL ALPHA & OMEGA SEMICONDUCTOR
ADM ARCHER-DANIELS-MIDLAND COMPANY
SHW SHERWIN-WILLIAMS COMPANY
WMB WILLIAMS COMPANIES INC.
PFE PFIZER INC.
TTEC TTEC HOLDINGS INC.
INVA INNOVIVA INC.
TM. TOYOTA MOTOR CORP. (ADS)
KDP KEURIG DR PEPPER INC.
NIO NIO INC. SPONSORED ADR CLASS A
NLOK NORTONLIFELOCK INC.
TWST TWIST BIOSCIENCE
ITOS ITEOS THERAPEUTICS
BILL BILL.COM HOLDINGS
BEAM BEAM THERAPEUTICS
HRMY HARMONY BIOSCIENCES HOLDINGS
CTKB CYTEK BIOSCIENCES INC
EVA ENVIVA PARTNERS LP
Moody's assigns A2 rating to Eli Lilly's sr. notes; positive outlook
Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes offering of Eli Lilly and Company ("Lilly"). There are no changes to Lilly's other ratings including the A2 senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unchanged ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Many Indexes and Sectors Testing Resistance Note: This Compass is an abbreviated report. We will resume our normal report layout next week. In our previous Compass (Jan. 24), we discussed our belief that equities were still in the midst of a rally/short squeeze, but that the rally is likely to fizzle in the 4100-4165 area (the top-end of our expected 2023 trading range) on the S&P 500. And, as you will see below, countless other indexes and Sectors are testing important resistance levels. We c...
- Pelham Smithers
- Pelham Smithers
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.